CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 120 enrolled
Drug / intervention
NuvaRingdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02445989
NCT02445989Phase 4Completed
CompareCT.gov

Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity

University of Washington·interventional·Posted May 15, 2015·Updated Dec 10, 2018

In Brief

A Phase 4 clinical trial evaluating NuvaRing for Bacterial Vaginosis and HIV. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The investigators propose to explore the hypothesis-supported by limited data-that a contraceptive vaginal ring (CVR) that is commonly used in the United States, the NuvaRing, will enhance women's genital and reproductive health. The investigators propose that this CVR will increase the bacteria that help the vaginal environment protect against infection by HIV and other STIs, and that in women who already have HIV, use of the CVR will lower the quantity of HIV that is shed in the female genital tract.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Vaginosis, HIV
CountriesKenya
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 15, 2015
Enrollment StartMay 1, 2016
Primary CompletionNov 1, 2018
Study CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.1 years ago

Interventions

NuvaRingdrug

Provide NuvaRing to women seeking contraception